Novartis Delivers Strong Innovation in 2012, Offsetting Patent Expirations

Novartis delivers strong innovation in 2012, offsetting patent expirations
Filed under: integrated treatment for dual diagnosis

Core operating income increased by 13% (+15% cc) to USD 899 million as a result of sales growth, productivity gains and the realization of post-integration synergies. Core operating income margin in constant currencies increased by 2.3 percentage …
{Source}